000296020 001__ 296020
000296020 005__ 20250130152059.0
000296020 0247_ $$2doi$$a10.1002/cncr.35620
000296020 0247_ $$2pmid$$apmid:39711146
000296020 0247_ $$2ISSN$$a1934-662X
000296020 0247_ $$2ISSN$$a0008-543X
000296020 0247_ $$2ISSN$$a1045-7410
000296020 0247_ $$2ISSN$$a1097-0142
000296020 0247_ $$2ISSN$$a1934-6638
000296020 0247_ $$2altmetric$$aaltmetric:172342778
000296020 037__ $$aDKFZ-2024-02763
000296020 041__ $$aEnglish
000296020 082__ $$a610
000296020 1001_ $$00009-0009-1571-8959$$aNguyen, Timothy$$b0
000296020 245__ $$aCoffee and tea consumption and the risk of head and neck cancer: An updated pooled analysis in the International Head and Neck Cancer Epidemiology Consortium.
000296020 260__ $$aNew York, NY$$bWiley-Liss$$c2025
000296020 3367_ $$2DRIVER$$aarticle
000296020 3367_ $$2DataCite$$aOutput Types/Journal article
000296020 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1738246819_13605
000296020 3367_ $$2BibTeX$$aARTICLE
000296020 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000296020 3367_ $$00$$2EndNote$$aJournal Article
000296020 500__ $$a2025 Jan 15;131(2):e35620
000296020 520__ $$aThe relations between coffee and tea consumption and head and neck cancer (HNC) incidence are unclear. With increasing global HNC burden, this study aims to examine the association between coffee, tea, and HNC.A pooled analysis of 9548 HNC cases and 15,783 controls from 14 individual-level case-control studies was conducted from the International Head and Neck Cancer Epidemiology consortium. Random-effects logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for HNC and its subsites, adjusting for sociodemographic and lifestyle factors.Compared to non-coffee drinkers, drinking >4 cups of caffeinated coffee daily was inversely associated with HNC (OR, 0.83; 95% CI, 0.69-1.00), oral cavity (OR, 0.70; 95% CI, 0.55-0.89), and oropharyngeal cancers (OR, 0.78; 95% CI, 0.61-0.99). Drinking 3-4 cups of caffeinated coffee was inversely associated with hypopharyngeal cancer (OR, 0.59; 95% CI, 0.39-0.91). Drinking decaffeinated coffee and drinking between >0 to <1 cup daily were inversely associated with oral cavity cancer (OR, 0.75; 95% CI, 0.64-0.87 and OR, 0.66; 95% CI, 0.54-0.81). Drinking tea was inversely associated with hypopharyngeal cancer (OR, 0.71; 95% CI, 0.59-0.87). Daily tea consumption of >0 to ≤1 cup was inversely associated with HNC (OR, 0.91; 95% CI, 0.84-0.98) and hypopharyngeal cancer (OR, 0.73; 95% CI, 0.59-0.91), but drinking >1 cup was associated with laryngeal cancer (OR, 1.38; 95% CI, 1.09-1.74).These findings support reduced HNC risk among coffee and tea drinkers. Future studies are needed to address geographical differences in types of coffee and tea to improve our understanding of the association of coffee and tea and global HNC risk.
000296020 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000296020 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000296020 650_7 $$2Other$$acoffee and tea
000296020 650_7 $$2Other$$ahead and neck cancer
000296020 650_7 $$2Other$$apooled analysis
000296020 7001_ $$00009-0003-9943-2945$$aKoric, Alzina$$b1
000296020 7001_ $$00000-0002-0878-997X$$aChang, Chun-Pin Esther$$b2
000296020 7001_ $$aBarul, Christine$$b3
000296020 7001_ $$aRadoi, Loredana$$b4
000296020 7001_ $$aSerraino, Diego$$b5
000296020 7001_ $$00000-0003-1177-3108$$aPurdue, Mark P$$b6
000296020 7001_ $$aKelsey, Karl T$$b7
000296020 7001_ $$aMcClean, Michael D$$b8
000296020 7001_ $$aNegri, Eva$$b9
000296020 7001_ $$aEdefonti, Valeria$$b10
000296020 7001_ $$00000-0002-4678-2058$$aMoysich, Kirsten$$b11
000296020 7001_ $$aZhang, Zuo-Feng$$b12
000296020 7001_ $$aMorgenstern, Hal$$b13
000296020 7001_ $$aLevi, Fabio$$b14
000296020 7001_ $$aVaughan, Thomas L$$b15
000296020 7001_ $$aLa Vecchia, Carlo$$b16
000296020 7001_ $$aGaravello, Werner$$b17
000296020 7001_ $$aHayes, Richard B$$b18
000296020 7001_ $$aBenhamou, Simone$$b19
000296020 7001_ $$aSchantz, Stimson P$$b20
000296020 7001_ $$aYu, Guo-Pei$$b21
000296020 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b22$$udkfz
000296020 7001_ $$00000-0002-1190-5687$$aChuang, Shu-Chun$$b23
000296020 7001_ $$00000-0002-3811-2791$$aBoffetta, Paolo$$b24
000296020 7001_ $$aHashibe, Mia$$b25
000296020 7001_ $$aLee, Yuan-Chin Amy$$b26
000296020 773__ $$0PERI:(DE-600)1479932-7$$a10.1002/cncr.35620$$gp. cncr.35620$$n2$$pe35620$$tCancer$$v131$$x0008-543X$$y2025
000296020 909CO $$ooai:inrepo02.dkfz.de:296020$$pVDB
000296020 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000296020 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000296020 9141_ $$y2024
000296020 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-21$$wger
000296020 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000296020 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000296020 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000296020 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000296020 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000296020 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000296020 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000296020 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000296020 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000296020 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000296020 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER-AM CANCER SOC : 2022$$d2023-10-21
000296020 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000296020 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000296020 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER-AM CANCER SOC : 2022$$d2023-10-21
000296020 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000296020 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000296020 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPrimäre Krebsprävention$$x2
000296020 980__ $$ajournal
000296020 980__ $$aVDB
000296020 980__ $$aI:(DE-He78)C070-20160331
000296020 980__ $$aI:(DE-He78)HD01-20160331
000296020 980__ $$aI:(DE-He78)C120-20160331
000296020 980__ $$aUNRESTRICTED